share_log

康哲藥業：截至二零二四年六月三十日止六個月之中期業績公告及董事調任

CMS: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024 AND RE-DESIGNATION OF DIRECTOR

HKEX ·  Aug 15 22:08

Summary by Futu AI

康哲藥業控股有限公司（CMS）公佈截至2024年6月30日止六個月的未經審計中期業績，營業額同比下降21.7%，至人民幣3,611.1百萬元。毛利同比下降25.2%，至人民幣2,696.5百萬元。期間溢利同比下降52.8%，至人民幣903.4百萬元。每股基本盈利同比下降52.3%，至人民幣0.3734元。公司宣派中期股息每股人民幣0.1507元，同比下降51.9%。公司表示，國家帶量採購對業績產生負面影響，但標誌著國採對公司的負面影響已基本消化。公司將持續推動創新產品的佈局、臨床開發進程，推出更多創新產品上市銷售，驅動集團取得持續的高質量發展。此外，陳洪兵先生辭任首席營運官及副總裁，由執行董事調任為非執行董事，並獲聘為資深顧問。
康哲藥業控股有限公司（CMS）公佈截至2024年6月30日止六個月的未經審計中期業績，營業額同比下降21.7%，至人民幣3,611.1百萬元。毛利同比下降25.2%，至人民幣2,696.5百萬元。期間溢利同比下降52.8%，至人民幣903.4百萬元。每股基本盈利同比下降52.3%，至人民幣0.3734元。公司宣派中期股息每股人民幣0.1507元，同比下降51.9%。公司表示，國家帶量採購對業績產生負面影響，但標誌著國採對公司的負面影響已基本消化。公司將持續推動創新產品的佈局、臨床開發進程，推出更多創新產品上市銷售，驅動集團取得持續的高質量發展。此外，陳洪兵先生辭任首席營運官及副總裁，由執行董事調任為非執行董事，並獲聘為資深顧問。
CMS Holdings Ltd. announced the unaudited interim performance for the six months ended June 30, 2024. Revenue decreased by 21.7% year-on-year to RMB 361.11 million. Gross profit decreased by 25.2% year-on-year to RMB 269.65 million. During the period, net profit attributable to shareholders decreased by 52.8% year-on-year to RMB 90.34 million. Basic earnings per share decreased by 52.3% year-on-year to RMB 0.3734. The company declared an interim dividend of RMB 0.1507 per share, a decrease of 51.9% year-on-year. The company stated that the national centralized procurement has had a negative impact on performance, but the negative impact on the company has been basically digested. The company will continue to promote the layout of innovative products, clinical development progress, launch more innovative products for sales, and drive the group to achieve sustained high-quality development. In addition, Mr. Chen Hongbing resigned as Chief Operating Officer and Vice President, and was appointed as a non-executive director and senior consultant by the company.
CMS Holdings Ltd. announced the unaudited interim performance for the six months ended June 30, 2024. Revenue decreased by 21.7% year-on-year to RMB 361.11 million. Gross profit decreased by 25.2% year-on-year to RMB 269.65 million. During the period, net profit attributable to shareholders decreased by 52.8% year-on-year to RMB 90.34 million. Basic earnings per share decreased by 52.3% year-on-year to RMB 0.3734. The company declared an interim dividend of RMB 0.1507 per share, a decrease of 51.9% year-on-year. The company stated that the national centralized procurement has had a negative impact on performance, but the negative impact on the company has been basically digested. The company will continue to promote the layout of innovative products, clinical development progress, launch more innovative products for sales, and drive the group to achieve sustained high-quality development. In addition, Mr. Chen Hongbing resigned as Chief Operating Officer and Vice President, and was appointed as a non-executive director and senior consultant by the company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated